This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by highlighting this unique role that HIV MTCT plays in understanding the immune correlates of protection and provide an overview of key aspects of MTCT including the epidemiology, transmission, and current prevention methods.
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by covering transcription regulation of human immunodeficiency virus type 1 (HIV-1) gene expression, focusing on the invaluable contributions, made by HIV research over the years, toward the field of transcription.
This chapter aligns with the SDG goal 3 of good health and wellbeing by showing the role of AGEs and RAGE in liver fibrosis and inflammation.
The WHO global health sector strategy on viral hepatitis, created in May, 2016, aims to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortality due to hepati
In 2016, WHO adopted a strategy for the elimination of viral hepatitis by 2030.
Background Multistage, stepwise HIV testing and treatment procedures can result in lost opportunities to provide timely antiretroviral therapy (ART).
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by discussing the impact of chromatin structure on viral integration, transcriptional regulation and latency, and the host factors that influence HIV-1 replication by regulating chromatin organization.
Background & Aims Coffee has anti-inflammatory and hepato-protective properties.
This chapter aligns with the SDG goal 3 of good health and wellbeing by examining the public health and economic burden of hepatitis C infection in developing countries.
The report is authored by over 50 leading oncologists, including members of leading US cancer organizations, and sets out 13 key priority areas, each with measurable goals, to focus the $2 billion of funding released to the National Cancer Institute (NCI) as part of the 21st Century Cures Act. The report sets out a detailed road map to deliver on the Blue Ribbon Panel recommendations, including a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups.
